Practical considerations for the integration of subcutaneous targeted therapies into the oncology clinic

Angela Boudreau


The oncology clinic is changing, with an increasing number of cancer therapies becoming available as formulations for subcutaneous (SC) injection. Using targeted therapies, such as alemtuzumab, bortezomib, rituximab or trastuzumab, via SC injection can be advantageous for patients, healthcare professionals, and healthcare systems. However, their use can also present challenges, and nurses have a unique opportunity to positively influence the integration of SC agents in the clinic. This article summarizes practical suggestions for optimal administration of SC targeted therapies, and provides pragmatic considerations for managing the change process related to their adoption. 

Full Text:



Barrow, J. M., & Toney-Butler, T. J. (2019). Change Management. In StatPearls. Retrieved from

BC Cancer Agency. (2015). BC Cancer Agency Drug Manual: alemtuzumab. Retrieved from

Carlson, J., Cox, K., Bedwell, K., & Ku, M. (2015). Rituximab for subcutaneous delivery: Clinical management principles from a nursing perspective. International Journal of Nursing Practice, 21(S3), 1–13.

Davidson, J. (2015). What’s all the buzz about change management? Healthcare Management Forum, 28(3), 118–120.

Davies, A., Berge, C., Boehnke, A., Dadabhoy, A., Lugtenburg, P., Rule, S., … Badoux, X. (2017). Subcutaneous Rituximab for the treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Advances in Therapy, 34(10), 2210–2231.

De Cock, E., Pivot, X., Hauser, N., Verma, S., Kritikou, P., Millar, D., & Knoop, A. (2016). A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer. Cancer Medicine, 5(3), 389–397.

Dent, S., Ammendolea, C., Christofides, A., Edwards, S., Incekol, D., Pourmirza, B., … Poirier, B. (2019). A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer. Current Oncology, 26(1), e70–e80.

Haller, M. F. (2007). Converting intravenous dosing to subcutaneous dosing with recombinant human hyaluronidase. Pharmaceutical Technology, 31(10). Retrieved from

Hoffmann-La Roche Ltd. (2018a). HERCEPTIN SC (trastuzumab) Product Monograph. Retrieved from

Hoffmann-La Roche Ltd. (2018b). RITUXAN SC (rituximab) Product Monograph. Retrieved from

Jackisch, C., Müller, V., Maintz, C., Hell, S., & Ataseven, B. (2014). Subcutaneous administration of monoclonal antibodies in oncology. Geburtshilfe Und Frauenheilkunde, 74(4), 343–349.

Janssen Inc. (2018). VELCADE (bortezomib) Product Monograph. Retrieved from

Kurtin, S., Knop, C. S., & Milliron, T. (2012). Subcutaneous administration of Bortezomib: Strategies to reduce injection site reactions. Journal of the Advanced Practitioner in Oncology, 3(6), 406–410.

Leveque, D. (2014). Subcutaneous administration of anticancer agents. Anticancer Research, 34(4), 1579–1586.

Lundin, J., Kimby, E., Björkholm, M., Broliden, P.-A., Celsing, F., Hjalmar, V., … Österborg, A. (2002). Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 100(3), 768–773.

MacDonald, D., Crosbie, T., Christofides, A., Assaily, W., & Wiernikowski, J. (2017). A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma. Current Oncology, 24(1), 33–39.

Martin, J. (2013). The subcutaneous administration of Bortezomib Practice Guideline Capstone Project (Regis University). Retrieved from

Martin, J. R., Beegle, N. L., Zhu, Y., & Hanisch, E. M. (2015). Subcutaneous administration of Bortezomib: A pilot survey of oncology nurses. Journal of the Advanced Practitioner in Oncology, 6(4), 308–318.

Möbus, V., Mahlberg, R., Janni, W., Tomé, O., Marmé, F., Forstbauer, H., … Loibl, S. (2018). Abstract P5-20-09: Pharmacokinetic results of a subcutaneous injection of trastuzumab into the thigh versus into the abdominal wall in patients with HER2-positive primary breast cancer (BC) treated within the neo-/adjuvant GAIN-2 study. Cancer Research, 78(4 Suppl.), P5-20-09–P5-20–09.

Pivot, X., Verma, S., Fallowfield, L., Müller, V., Lichinitser, M., Jenkins, V., … Gligorov, J. (2017). Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study. European Journal of Cancer, 86, 82–90.

Platzbecker, U., Aul, C., Ehninger, G., & Giagounidis, A. (2010). Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil. Annals of Hematology, 89(4), 427–428.

Sanofi Genzyme. (2018). MABCAMPATH (alemtuzumab) Product Monograph. Retrieved from

Stilgenbauer, S., Zenz, T., Winkler, D., Bühler, A., Schlenk, R. F., Groner, S., … Döhner, H. (2009). Subcutaneous Alemtuzumab in Fludarabine-Refractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the CLL2H Ssudy of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology, 27(24), 3994–4001.


  • There are currently no refbacks.